期刊文献+

蛋白酶体抑制诱导的PC12细胞帕金森病模型 被引量:3

Parkinson Disease Model of PC12 Cell Induced by Proteasomal Inhibition
下载PDF
导出
摘要 目的探讨蛋白酶体抑制剂对PC12细胞的作用以及用该药物制作帕金森病(PD)模型的可能性。方法用不同浓度蛋白酶体抑制剂PSI作用于PC12细胞24、48、72h后,以MTT法检测细胞活性,荧光染色检测凋亡细胞百分率,HE染色观察细胞形态变化,透射电镜观察细胞超微结构变化。结果不同浓度PSI作用于PC12细胞24h时,细胞存活率无变化;作用48-72h时,1~20μmol/LPSI使细胞存活率分别降至47.03%~58.98%和19.58%~34.72%;凋亡细胞由1.15%升至5.27%。HE染色显示经PSI处理的PC12细胞胞浆内有嗜酸性包涵体出现,透射电镜下细胞呈凋亡的超微结构特点。结论PC12细胞蛋白酶体受抑模拟了PD的两大病理特点,蛋白酶体功能异常可能是PD的发病因素之一,短期抑制PC12细胞的蛋白酶体功能可作为PD的细胞模型。 Obieetive To study the Parkinson model of PC12 cells induced by proteasomal inhibition(PSI). Methads The viability of PC12 cells was assayed by MTT, after incubation in different-concentrations of PSI for different periods ( 24,48 or 72 h) ; the apoptotic proportion was calculated after fluorescent stain;configuration of the cells were observed cytological and ultrastructural by HE stain and transmission electron microscopy. ResultsThe viability of PC12 cells was not influenced by incubation with PSI for 24 hours , but it was decreased to 47.03%-58. 98% and 19.58%-34. 72% by incubation with 1-20 μmol/L PSI for 48 and 72 h respectively. According to fluorescent stain observation, the proportion of apoptotic cell increased from 1.15% to 5.27%. Eosinophilic cytoplasmic inclusion was detected in PC12 cells treated with PSI after HE stain. Ultrastructural changes of apoptosis could be observed in some of the cells by transmission electron microscopy. Conclusions The two most important pathologic ultrastructural features of Parkinson disease can be induced in PC12 cells by treatment of proteasomal inhibitor PSI. Proteasomal dysfunction may be one of the pathogenetic factors of Parkinson disease and short-time inhibition of proteasome function can be used as a cell model of Parkinson disease.
出处 《中国神经免疫学和神经病学杂志》 CAS 2006年第6期360-363,共4页 Chinese Journal of Neuroimmunology and Neurology
基金 吉林省科技厅科研基金资助项目(200505200)
关键词 蛋白酶体抑制 PC12细胞 帕金森病 Proteasomal inhibition PC12 cell Parkinson disease
  • 相关文献

参考文献6

  • 1Betarbet R,Sherer TB,Greenamyre JT.Ubiquitin-proteasome system and Parkinson's disease[J].Exp Neurol,2005,191:s17-s27.
  • 2Das PC,McElroy WK,Cooper RL.Potential mechanisms responsible for chlorotriazine-induced alterations in catecholamines in pheochromocytoma (PC12) cells[J].Life Sci,2003,73(24):3123-3138.
  • 3Tompkins MM,Basgall EJ,Zamrini E,et al.Apoptotic-like changes in Lewy-body-associated disorders and nomal aging in subtantia nigral neurons[J].Am J Pathol,1997,150(1):119-131.
  • 4Kowall NW,Hantraye P,Brouillet alE,et al.MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons[J].Neuro Report,2000,11(1):211-213.
  • 5Sherer TB,Kim JH,Betarbet R,et al.Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation[J].Exp Neurol,2003,179(1):9-16.
  • 6McNaught KS,Perl DP,Brownell AL,et al.Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease[J].Ann Neurol,2004,56(1):149-162.

同被引文献82

  • 1梅加明,牛朝诗,陈建民,倪永丰.蛋白酶体抑制剂诱导帕金森病大鼠模型行为学退行性改变的研究[J].中国微侵袭神经外科杂志,2008,13(10):466-469. 被引量:8
  • 2裴媛,马进,李姗.帕金森病模型的研究进展[J].中国老年学杂志,2014,34(2):543-547. 被引量:10
  • 3徐卉,常明,张磊,杜丹华,胡林森.6-羟基多巴胺诱导PC12细胞帕金森模型中GRP78表达的研究[J].中风与神经疾病杂志,2007,24(2):154-156. 被引量:3
  • 4McNaught KS, Jackson T, JnoBaptiste R, et al. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology, 2006, 66 ( 10Suppl4): s37-s49.
  • 5McNaught KS, Perl DP, Brownell AL, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol, 2004, 56 (1): 149-162.
  • 6Zhang L, Chang M, Li H, et al. Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI. Brain Res, 2007, 1153 (11): 196-203.
  • 7Basso M, Giraudo S, Corpillo D, et al. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics, 2004, 4 (12): 3943-3952.
  • 8Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol, 1995, 38 (3): 379-388.
  • 9McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci, 2001.2 (8): 589-594.
  • 10Rideout HJ, Larsen KE, Sulzer D, et al. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem, 2001, 78 (4): 899-908.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部